Full Press Release Details
Named to Deloitte Technology Fast 50 China
November 3, 8:00 am ET
Nov. 3 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA - News), a
vaccine-focused biotech company in China, announced today its Beijing-based
subsidiary and main operating entity, Sinovac Beijing, was named to the Deloitte
Technology Fast 50 China 2008. The results were announced on October 31, 2008 at
a special ceremony in Shenzhen. Dr. Yin Weidong, general manager of Sinovac
Beijing and President and CEO of Sinovac Biotech, attended the award ceremony
and the CEO Forum for Fast Growth Companies.
commented, "Sinovac Beijing has been a leader in the human vaccine industry with
its inactivated hepatitis A vaccine, Healive(TM), and has commanded the leading
market position in China. We are pleased to receive this award that recognizes
our high growth of 290% over the past three years. We continue to advance our
vaccine technology and leverage our market advantages to increase sales of our
commercialized vaccines. We are well positioned to continue our growth in light
of the world financial crisis and increasing competition."
part of the Deloitte Technology Fast 500 Asia Pacific program, the Deloitte
Technology Fast 50 China ranking includes the 50 fastest growing technology,
media, telecommunications and life sciences companies in China and the Asia
Pacific region. The Fast 50 China 2008, as determined by Deloitte & Touche,
LLP, a US-based professional services organization, aims to reward and raise the
visibility of the companies with highest growth rates. Among the 2008 China
recipients, six companies come from biotechnology and pharmaceutical industry,
representing 12%, a 4% increase compared to the last year. The increase
demonstrates the rapid development and expansion of the life sciences industry
conjunction with the awards ceremony, Deloitte released the "CEO Survey Report
on Deloitte's Technology Fast 50 China 2008." The report noted that the rapid
development of technology leads to research advances, new technology, and new
products. Approximately 60% of interviewed CEOs believe the organic growth based
on new technologies and products has greatly promoted business
to last year, Chinese growth companies continue to have a high regard for growth
prospects across the Asia Pacific region. 71% of the surveyed companies have an
optimistic view of development in the region. These CEOs also believe the Asia
Pacific region presents the most attractive market growth opportunities.
Additionally, 77% of CEOs said they pay much more attention to the regional
market, which is attracting enterprises seeking advanced development
about future, 94% of CEOs remain confident that the region will continue to
experience a high growth rate over the next 12 months. 46% of CEOs do not
believe the world economic depression has affected their business. They are
actively adopting corresponding measures, such as attracting talent from
developed markets and seeking acquisition opportunities in the developed
Deloitte Technology Fast 50
Deloitte Technology Fast 50 program started in 1995 in San Jose. This program
quickly expanded to numerous cities and countries. In 2005, Deloitte China
launched the "Deloitte Technology Fast 50 China" program. Participants in the
Deloitte Technology Fast 50 China program will automatically qualify for
participation in the Deloitte Technology Fast 500 Asia Pacific 2008 program,
which annually recognises the 500 fastest growing technology companies in Asia
Biotech Ltd. is a China-based biopharmaceutical company that focuses on the
research, development, manufacture and commercialization of vaccines that
protect against human infectious diseases. Sinovac's commercialized vaccines
include Healive (hepatitis A), Bilive (combined hepatitis A and B), Anflu
(influenza) and Panflu(TM) (H5N1). Sinovac is currently developing Universal
Pandemic Influenza vaccine and Japanese encephalitis vaccine. Additional
information about Sinovac is available on its website, http://www.sinovac.com
. To be added to our distribution list, please email: info@sinovac.com.
announcement contains forward-looking statements. These statements are made
under the "safe harbor" provisions of the U.S. Private Securities Litigation
Reform Act of 1995. These forward-looking statements can be identified by words
or phrases such as "will," "expects," "anticipates," "future," "intends,"
"plans," "believes," "estimates" and similar statements. Among other things, the
business outlook and quotations from management in this press release contain
forward-looking statements. Statements that are not historical facts, including
statements about Sinovac's beliefs and expectations, are forward-looking
statements. Forward-looking statements involve inherent risks and uncertainties.
A number of important factors could cause actual results to differ materially
from those contained in any forward-looking statement. Sinovac does not
undertake any obligation to update any forward-looking statement, except as
required under applicable law.
more information, please contact:
Tel: +86-10-8289-0088
Fax: +86-10-6296-6910
Carrington / Janine McCargo
Tel: +1-646-536-7017/7033